Janus Kinase Jak Inhibitors Competitive Landscape Pipeline Market Analysis

DelveInsight’s, “Janus Kinase (JAK) Inhibitors- Competitive Landscape, Pipeline and Market Analysis, 2017”, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Janus Kinase (JAK) Inhibitors. This report provides information on the therapeutic development based on Janus Kinase (JAK) Inhibitors mechanism of action dealing with around 20+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. DelveInsight’s Report also assesses the Janus Kinase (JAK) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products.

Scope

• The report provides competitive pipeline landscape of Janus Kinase (JAK) Inhibitors

• The report provides the marketed drugs information including its sales, development activities and details of patent expiry

• The report provides the insight of current and future market for Janus Kinase (JAK) Inhibitors

• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information

• Coverage of the Janus Kinase (JAK) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

• The report reviews key players involved in the therapeutics development for Janus Kinase (JAK) Inhibitors and also provide company profiling

• The report also gives the information of dormant pipeline projects

• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages

• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Reasons to Buy

• Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage

• Complete MOA intelligence and complete understanding over therapeutics development for Janus Kinase (JAK) Inhibitors

• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.

• Devise corrective measures for pipeline projects by understanding Janus Kinase (JAK) Inhibitors pipeline depth and focus of Indication therapeutics

• Developing strategic initiatives to support your drug development activities.

• Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.

• Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

• Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Introduction

Executive Summary

Executive Summary Snapshot

Janus kinase Inhibitors (JAK Inhibitors) Overview

Introduction

Structure and Mechanism

Janus Kinase Inhibitors

Types of JAK Inhibitors

Cytokines associated with Janus kinases and result of their mutations

JAK Inhibitors Market Analysis

Collaborations and Deals

Acquisition Deals

Designations Analysis

Grants

Financing

Companies Involved in JAK Inhibitor Development

Therapeutic Targets by Company and Indication

Market Drivers and Barriers

Drivers

Barriers

Marketed Products

Therapeutics under Development by Companies

Late Stage Products (Filed &Phase III)

Comparative Analysis

Mid Stage Products (Phase II)

Comparative Analysis

Early Stage Products (Phase Iand IND)

Comparative Analysis

Discovery and Pre-clinical stage Products

Comparative Analysis

Therapeutic Assessment

Assessment by Monotherapy Products

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Dormant Products

Companies involved in Therapeutics Development

Upcoming Conferences

SWOT Analysis for JAK Inhibitors

Appendix

Methodology

Consulting Services

About DelveInsight

Contact Us

Disclaimer

Table 1:Collaboration and Deal Values for JAK Inhibitors, 2017

Table 2:Acquisition deals for the development of JAK Inhibitors , 2017

Table 3: Grants, 2017

Table 4:Number of Products Under Development for Janus Kinase (JAK) Inhibitors, 2017

Table 5: Number of Products under Development by Companies, 2017

Table 6: Late Stage Products (Filed &Phase III),2017

Table 7: Mid Stage Products (Phase II),2017

Table 8: Early Stage Products (Phase Iand IND), 2017

Table 9: Discovery and Pre-clinical stage Products, 2016

Table 10: Assessment by Monotherapy Products, 2017

Table 11: Assessment by Route Of Administration, 2017

Table 12:Assessment by Stage and Route Of Administration, 2017

Table 13: Assessment by Molecule Type, 2017

Table 14: Assessment by Stage and Molecule Type, 2017

Table 15: Dormant Products, 2017

Table 16: Discontinued Products, 2016

Table 17: AbbVie, Overview, 2017

Table 18: Aclaris Therapeutics, Inc., Overview, 2017

Table 19: Advinus Therapeutics, Overview, 2017

Table 20: Amgen Inc., Overview, 2017

Table 21: Aptose Biosciences, Overview, 2017

Table 22: Arrien Pharmaceuticals, Overview, 2017

Table 23: Asana BioSciences, Overview, 2017

Table 24: Astellas Pharma Inc., Overview, 2017

Table 25: Astrazeneca, Overview, 2017

Table 26:Bristol-Myers Squibb, Overview, 2017

Table 27: CleveXel Pharma, Overview, 2017

Table 28: Cloud pharmaceuticals, Overview, 2017

Table 29: Concert Pharmaceuticals, Overview, 2017

Table 30: CTI BioPharma, Overview, 2017

Table 31: Cytopia Research, Overview, 2017

Table 32: Eli Lilly and Company, Overview, 2017

Table 33: Galapagos NV, Overview, 2017

Table 34: Gilead Sciences, Overview, 2017

Table 35: Hoffmann-La Roche, Overview, 2017

Table 36: Incyte Corporation, Overview, 2017

Table 37: Japan Tobacco Company, Overview, 2017

Table 38: Nimbus Therapeutics, Overview, 2017

Table 39: Pfizer Inc., Overview, 2017

Table 40: Portola Pharmaceuticals, Overview, 2017

Table 41: Sareum Limited, Overview, 2017

Table 42: Theravance Biopharma, Overview, 2017

Table 43: Tragara Pharmaceuticals, Overview, 2017

Table 44: Vectura Group, Overview, 2017

Figure 1: Structure of Janus Kinase

Figure 2: Illustrated mechanism of Janus Kinase

Figure 3: Collaboration and Deals for JAK Inhibitors, 2017

Figure 4: Number of Companies under acquisition for JAK Inhibitors, 2017

Figure 5: Designation Analysis for JAK Inhibitors, 2017

Figure 6: Grants, 2017

Figure 7: Number of Products under Development for JAK Inhibitor, 2017

Figure 8: Number of Products under Development for Janus Kinase(JAK) Inhibitors, 2017

Figure 9: Late Stage Products (Filed &Phase III),2017

Figure 10: Mid Stage Products (Phase II),2017

Figure 11:Early Stage Products (Phase Iand IND ), 2017

Figure 12: Discovery and Pre-clinical stage Products, 2016

Figure 13: Number of Products under Development forJAK Inhibitors,2017

Figure 14: Assessment by Route of Administration, 2017

Figure 15: Assessment by Stage and Route of Administration,2017

Figure 16: Assessment by Molecule Type,2017

Figure 17: Assessment by Stage and Molecule Type,2017

Figure 18: Dormant Products, 2017

Figure 19:Discontinued Products, 2016

Aptose Biosciences

Astellas Pharma

Theravance Biopharma

Theravance Biopharma

Vectura Group plc

Japan Tobacco Company

Hoffmann-La Roche

Astrazeneca

AbbVie

Galapagos NV

Incyte Corporation

Pfizer

Incyte Corporation

Advinus Therapeutics

Cloud pharmaceuticals

Eli Lilly and Company

Bristol-Myers Squibb

CTI BioPharma

Tragara Pharmaceuticals

Amgen

Cloud pharmaceuticals

Cloud pharmaceuticals

Portola Pharmaceuticals

Asana BioSciences

Eli Lilly and Company

Gilead Sciences

Concert Pharmaceuticals

Aclaris Therapeutics International Limited (ATIL)

Aclaris Therapeutics International Limited (ATIL)

Advinus Therapeutics

CleveXel Pharma

Arrien Pharmaceuticals

Nimbus Therapeutics

Sareum Limited

Sareum Limited

Cloud pharmaceuticals

Sareum Limited

  • Tags:
  • "• Therapy Pipeline scenario • Curr...
  • Technologies • Licensing opportuni...

Forward to Friend

Need A Quote